Regencell Bioscience Holdings Ltd (RGC) - Total Liabilities
Based on the latest financial reports, Regencell Bioscience Holdings Ltd (RGC) has total liabilities worth $895.31K USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Regencell Bioscience Holdings Ltd - Total Liabilities Trend (2003–2025)
This chart illustrates how Regencell Bioscience Holdings Ltd's total liabilities have evolved over time, based on quarterly financial data. See how liquid is Regencell Bioscience Holdings Ltd's working capital to evaluate short-term liquidity relative to the company's equity base.
Regencell Bioscience Holdings Ltd Competitors by Total Liabilities
The table below lists competitors of Regencell Bioscience Holdings Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Alpha Services and Holdings S.A.
AT:ALPHA
|
Greece | €64.85 Billion |
|
Capstone Mining Corp
TO:CS
|
Canada | CA$3.21 Billion |
|
Cirrus Logic Inc
NASDAQ:CRUS
|
USA | $361.38 Million |
|
The Federal Bank Limited
NSE:FEDERALBNK
|
India | Rs3.61 Trillion |
|
FSN E-Commerce Ventures Limited
NSE:NYKAA
|
India | Rs31.09 Billion |
|
Knight Transportation Inc
NYSE:KNX
|
USA | $4.86 Billion |
|
Sprott Physical Gold and Silver Trust
TO:CEF
|
Canada | CA$5.81 Million |
|
Als Ltd
AU:ALQ
|
Australia | AU$2.43 Billion |
Liability Composition Analysis (2003–2025)
This chart breaks down Regencell Bioscience Holdings Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see RGC market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Regencell Bioscience Holdings Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Regencell Bioscience Holdings Ltd (2003–2025)
The table below shows the annual total liabilities of Regencell Bioscience Holdings Ltd from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $895.31K | +307.86% |
| 2024-06-30 | $219.51K | -65.28% |
| 2023-06-30 | $632.32K | -32.59% |
| 2022-06-30 | $938.03K | -78.38% |
| 2021-06-30 | $4.34 Million | +37.06% |
| 2020-06-30 | $3.16 Million | +52.03% |
| 2019-06-30 | $2.08 Million | -99.94% |
| 2018-06-30 | $3.70 Billion | +6.14% |
| 2017-06-30 | $3.48 Billion | -0.72% |
| 2016-06-30 | $3.51 Billion | +2.20% |
| 2015-06-30 | $3.43 Billion | +0.47% |
| 2014-06-30 | $3.42 Billion | +17.61% |
| 2013-06-30 | $2.91 Billion | -0.20% |
| 2012-06-30 | $2.91 Billion | -2.37% |
| 2011-06-30 | $2.98 Billion | +3.41% |
| 2010-06-30 | $2.88 Billion | +1.53% |
| 2009-06-30 | $2.84 Billion | +3.20% |
| 2008-06-30 | $2.75 Billion | +10.61% |
| 2007-06-30 | $2.49 Billion | -0.48% |
| 2006-06-30 | $2.50 Billion | +1.21% |
| 2005-06-30 | $2.47 Billion | +47.70% |
| 2004-06-30 | $1.67 Billion | +61.49% |
| 2003-06-30 | $1.04 Billion | -- |
About Regencell Bioscience Holdings Ltd
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in… Read more